home / stock / sphs / sphs news

SPHS News and Press, Sophiris Bio Inc

Stock Information
Company Name: Sophiris Bio Inc
Stock Symbol: SPHS
Market: OTC
Website: sophirisbio.com
Menu
SPHS SPHS Quote SPHS Short SPHS News SPHS Articles SPHS Message Board
Get SPHS Alerts

News, Short Squeeze, Breakout and More Instantly...
SPHS - Sophiris Bio to shut down operations

Sophiris Bio plummets ( SPHS -96.3% ) after the company announces to immediately commence the process of shutting down of its operations. More news on: Sophiris Bio, Inc., Healthcare stocks news, Read more ...

SPHS - Sophiris Bio To Shut Down Operations

SAN DIEGO and VANCOUVER, British Columbia , May 18, 2020 /PRNewswire/ -- Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Compa...

SPHS - Sophiris Bio Announces Nasdaq Delisting

SAN DIEGO and VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the tre...

SPHS - Nymox Pharmaceuticals Has A Long History Of Broken Promises And Baffling Delays That Will Likely Continue

This article was highlighted for PRO+ subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here . Nymox Pharmaceutical Corp ( NYMX ) is the longest running failure that we have ever seen. The company started i...
SPHS - Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseas...

SPHS - Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

SAN DIEGO and VANCOUVER, British Columbia , Oct. 21, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for th...

SPHS - Sophiris Bio (SPHS) Investor Presentation - Slideshow

The following slide deck was published by Sophiris Bio, Inc. in conjunction with this Read more ...

SPHS - Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

SAN DIEGO and VANCOUVER, British Columbia , Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatmen...

SPHS - Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

SAN DIEGO and VANCOUVER, British Columbia , Aug. 30, 2019 /PRNewswire/  -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for ...

SPHS - Sophiris Bio Announces $4.0 Million Registered Direct Offering

SAN DIEGO and VANCOUVER, British Columbia , Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (Nasdaq: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of ...
Next 10